Brief: Oragenics Announces Positive Covid-19 Challenge Study Results Evaluating Multiple Formulations Of Its Sars-Cov-2 Vaccine Candidate
01/12/2021 13:25
Dec 1 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ANNOUNCES POSITIVE COVID-19 CHALLENGE STUDY
RESULTS
EVALUATING MULTIPLE FORMULATIONS OF ITS SARS-COV-2 VACCINE
CANDIDATE
* ORAGENICS INC - BOTH FORMULATIONS GENERATED ROBUST IMMUNE
RESPONSES
* ORAGENICS INC - BOTH FORMULATIONS REDUCED SARS-COV-2 VIRAL
LOADS
TO UNDETECTABLE LEVELS IN NASAL PASSAGES AND LUNGS FIVE DAYS
FOLLOWING A VIRAL CHALLENGE
* ORAGENICS INC - VACCINES DELIVERED BY INTRANASAL AND
INTRAMUSCULAR ROUTES GENERATED IMMUNE RESPONSES AS MEASURED BY
MULTIPLE ASSAYS
Source text for Eikon: ID:nBw7DnCTMa
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing